CyberKnife® Research at the Capital Health Center for Oncology
Research and clinical trials in oncology at Capital Health Center for Oncology is a major part of the total medical care we offer our patients. Due to the relatively new emergence of CyberKnife® radiosurgery in oncology and neurosurgery, ongoing research using this device is still active and therefore there are many national protocols that are available to our patients.
Over the past two years, we have identified and initiated protocols that investigate improved treatment methodology and efficiency for all patients using CyberKnife radiosurgery. Some of the protocols we have opened included treatment for brain, prostate and spine tumors, and in the next few months, we will start new CyberKnife clinical trials that involve treatment to prostate and spinal metastases.
To better serve our cancer patient population, we have also instituted several research studies that evaluate our treatment methods and outcomes. Listed below are the protocols and studies that are currently open for enrollment of patients.
Current Active Clinical Trials:
- CK Brain Mets-01 - A Phase II consensus multi-institutional trial of CyberKnife Radiosurgery to the operative cavity in patients with resected brain metastases. (Clinical Trial)
This clinical trial is open to all patients who have brain metastases, who are older than 18 years of age and have not previously received whole brain radiation. The standard treatment for patients who have tumor metastasis to the brain may include surgery and various forms of radiation therapy. Unfortunately, in the past, these treatments were not curative and could be toxic. This study is being done to evaluate a novel CyberKnife treatment combination for one to three metastatic cancerous tumors in the brain. The protocol involves surgery followed by focused beams of CyberKnife radiation. If you think you may qualify for this trial or have any further questions, please ask our radiation oncologist for more explanation about this study.
- ACR-Protocol V2 - The Access CyberKnife Patient Registry (Research Study)
The Access CyberKnife Registry is a Capital Health multi-year database designed to track CyberKnife patients, treatment practices and outcomes to help determine, over time, the most effective use of the CyberKnife System in management of patients with life threatening tumors and other diseases. The system is also useful as a way of recording the patient chart regarding information pertaining to CyberKnife screening, diagnosis, treatment and follow-up. This data can be used in research and to better manage the CyberKnife department.
- Retro Spine Mets 01 - Retrospective Analysis of Patient Outcomes Following CyberKnife Treatments Targeting Tumor Metastases to the Spine (Research Study)
CyberKnife radiosurgery plays an important role in the treatment of metastatic lesions to regions in and around the spine column. The primary goal of this study is to determine the efficacy of CyberKnife radiosurgery in treating painful spine metastases. The bulk of the data will be extracted from patients already treated with CyberKnife. In this retrospective study, we are investigating and reporting the rate of local tumor control, pain control, morbidity, and clinical outcomes of patients with metastatic spinal tumors treated with CyberKnife stereotactic radiosurgery.
- Retro Brain Mets CH 624 - Retrospective Analysis of Patient Outcomes Following CyberKnife Treatment to Brain Metastases (Research Study)
CyberKnife radiosurgery is used to treat critical intracranial metastatic lesions. This type of radiosurgery can often be used to treat patients who have received their limit of external beam radiation exposure. In this retrospective study, we are investigating and reporting the ability to achieve local tumor control, manage clinical symptoms and evaluate side-effects of patients with metastatic brain tumors treated with CyberKnife stereotactic radiosurgery.
For more information regarding clinical trials, please contact:
Research Nurse: Linda Andrzejewski, RN, at (609) 537-7042
Clinical Doctoral Research Coordinator: Derrick Grant, PhD, at (609) 537-4503